Curidium Joins the Personalized Medicine Coalition

Curidium Medica plc has announced that it has joined the US-based Personalized Medicine Coalition (PMC).

The PMC was publicly launched in November 2004 by more than a dozen pharmaceutical, biotechnology, diagnostics and information technology companies, along with major academic centers and governmental agencies.

An independent, non-profit group dedicated to advancing the understanding and adoption of personalized medicine concepts and products for the benefit of patients, it represents over 100 members. The Coalition seeks to promote discussion and understanding that will lead to the development of sound public policy on matters that affect the realization of personalized medicine.

“The PMC has become the key organization in shaping US public policy on personalized medicine. We believe the PMC will be instrumental in making personalized medicine a reality,” said Anne Bruinvels, CEO of Curidium Medica. “We are very pleased to be a member of a group that will dramatically impact the treatment of patients in the future.”

Edward Abrahams, Executive Director of the PMC, welcomed the addition of the UK-based personalized medicine company focused on psychiatric disorders. “Schizophrenia and bipolar disorder are indications that would benefit greatly from improved diagnostics and more targeted therapies. We look forward to Curidium’s involvement in the PMC’s activities.”